Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Breast Neoplasms 10Stomach Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Salivary Gland Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic HER2-positive Breast Cancer 1Hemangiosarcoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

spartalizumab 2durvalumab 2zanidatamab 1tremelimumab 1trastuzumab deruxtecan 1tislelizumab 1pembrolizumab 1obinutuzumab 1naptumomab estafenatox 1Trastuzumab 1Polymerase Chain Reaction 1Nivolumab 1Mass Spectrometry 1In Situ Hybridization, Fluorescence 1Immunohistochemistry 1Gemcitabine 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × zanidatamab × Breast × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡